



AFRL-RX-TY-TR-2009-4621

CHALLENGE OF N95 AND P100 FILTERING FACEPIECE RESPIRATORS WITH PARTICLE CONTAINING VIABLE H1N1

Joseph D. Wander
Air Force Research Laboratory
Airbase Technologies Division
139 Barnes Dr., Ste 2
Tyndall AFB, FL 32403-5323

Brian Heimbuch
Applied Research Associates
421 Oak Drive
Panama City, FL 32401

NIOSH IAA # 09-42
CDC Agreement IAA #09FED905877

December 2009

DISTRIBUTION A: Approved for public release; distribution unlimited.
AFCEC-201415; 1 May 2014.

**AIR FORCE RESEARCH LABORATORY
MATERIALS AND MANUFACTURING DIRECTORATE**

DISCLAIMER

Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement, recommendation, or approval by the United States Air Force. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Air Force.

This report was prepared as an account of work sponsored by the United States Air Force. Neither the United States Air Force, nor any of its employees, makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights

This document is submitted as an historical record of work performed. Limitations of the available media rendered editing impractical; therefore it is retained "as is."

NOTICE AND SIGNATURE PAGE

Using Government drawings, specifications, or other data included in this document for any purpose other than Government procurement does not in any way obligate the U.S. Government. The fact that the Government formulated or supplied the drawings, specifications, or other data does not license the holder or any other person or corporation; or convey any rights or permission to manufacture, use, or sell any patented invention that may relate to them.

This report was cleared for public release by the AFCEC Public Affairs Office at Joint Base San Antonio-Lackland Air Force Base, Texas available to the general public, including foreign nationals. Copies may be obtained from the Defense Technical Information Center (DTIC) (<http://www.dtic.mil>).

AFRL-RX-TY-TR-2009-4621 HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION IN ACCORDANCE WITH ASSIGNED DISTRIBUTION STATEMENT.

//SIGNED//

JOSEPH D. WANDER, PhD
Work Unit Manager

//SIGNED//

MICHAEL V. HENLEY, DR-III
Technical Advisor

This report is published in the interest of scientific and technical information exchange, and its publication does not constitute the Government's approval or disapproval of its ideas or findings.

REPORT DOCUMENTATION PAGE					Form Approved OMB No. 0704-0188	
The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.						
1. REPORT DATE (DD-MM-YYYY) 2-DEC-2009		2. REPORT TYPE Final Technical Report			3. DATES COVERED (From - To) 15 Mar-21 Nov 2009	
4. TITLE AND SUBTITLE Challenge of N95 and P100 Filtering Facepiece Respirators with Particles Containing Viable H1N1				5a. CONTRACT NUMBER NIOSH IAA # 09-42 ; CDC Agreement IAA #09FE		
				5b. GRANT NUMBER		
				5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Joseph D. Wander% and *Brian Heimbuch				5d. PROJECT NUMBER		
				5e. TASK NUMBER		
				5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) *Applied Research Associates 421 Oak Drive Panama City, FL 32401					8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) %Air Force Research Laboratory Materials and Manufacturing Directorate Airbase Technologies Division 139 Barnes Drive, Suite 2 Tyndall Air Force Base, FL 32403-5323					10. SPONSOR/MONITOR'S ACRONYM(S) AFRL/RXQL	
					11. SPONSOR/MONITOR'S REPORT NUMBER(S) AFRL-RX-TY-TR-2009-4621	
12. DISTRIBUTION/AVAILABILITY STATEMENT Distribution A: Approved for public release; distribution unlimited.						
13. SUPPLEMENTARY NOTES Ref Public Affairs Case # AFCEC-201415, 1 May 2014. Document contains color images.						
14. ABSTRACT 3M1860s (N95) and 3M 8293 (P100) NIOSH-approved filtering facepiece respirators (FFRs) were challenged with aerosolized particles of H1N1 influenza to measure the amount of viable influenza virus that penetrates each device. The test was conducted at the NIOSH-recommended flowrate of 85 LPM using guidance provided by a Department of Defense test standard developed for challenging air purification devices with viable microbial aerosols. The count mode diameter (CMD) particle size of the challenge aerosol was ~0.8 µm, which was created by aerosolizing H1N1 influenza virus in an artificial saliva buffer using the Laboratory-Scale Aerosol Tunnel (LSAT). In addition to the H1N1 challenge, each FFR was also challenged with 0.8-µm inert beads. In these tests the N95 FFR (<i>n</i> = 3) removed > 99% of the viable H1N1 from the air stream and the P100 (<i>n</i> = 3) removed > 99.99% of viable H1N1 from the airstream. The percent reductions in mechanical and viable particle counts measured for each FFR using the 0.8-µm bead challenge were equivalent to the percent reduction values measured for like-sized particles containing H1N1, verifying that bioaerosols act as typical particles. These data demonstrate that the N95 and P100 FFR will reduce viable H1N1 aerosol from the airstream at greater than or equal to their rated value.						
15. SUBJECT TERMS aerosol, FFR, H1N1, infection, influenza, N95, P100, respirator, respiratory						
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT SAR	18. NUMBER OF PAGES 35	19a. NAME OF RESPONSIBLE PERSON Joseph D. Wander	
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (Include area code) 850 283 6240	

Reset

Challenge of N95 and P100 Filtering Facepiece Respirators with Particles Containing Viable H1N1

NIOSH IAA # 09-42
CDC Agreement IAA #09FED905877

Submitted to:

Dr. Ron Shaffer
Chief, Technology Research Branch
NIOSH/NPPTL
P.O. Box 18070
Pittsburgh, PA 15236
Phone: (412) 386-4001
Email: rshaffer@cdc.gov



Submitted by:

Air Force Research Laboratory, RXQL
139 Barnes Drive, Suite 2
Tyndall Air Force Base, FL 32403

Joe Wander, Ph.D.
850-283-6240
joe.wander@tyndall.af.mil

Brian Heimbuch, M.Sc.
850-283-9724
brian.heimbuch@tyndall.af.mil



December 2, 2009

TABLE OF CONTENTS

Section	Title	Page
	Overview	1
	Executive Summary	1
1.0	Materials and Methods	2
1.1	Preparation of H1N1 Virus.....	2
1.2	Laboratory-Scale Aerosol Tunnel (LSAT).....	2
1.3	Preparation of Filtering Facepiece Respirators	3
1.4	H1N1 Filtration Studies.....	3
1.5	Viable Plating of H1N1 Influenza.....	3
1.6	Data Analysis	4
2.0	Results	5
3.0	Discussion	5
4.0	Summary	6
5.0	References	6
	Appendix I – H1N1 aerosol run forms	12
	Appendix II – H1N1 FFR challenge data.....	18
	Appendix III – Port correlation data	24
	Appendix IV – 0.8-µm bead challenge data.....	26
	List of Abbreviations, Acronyms, and Symbols.....	28

LIST OF FIGURES

Figure	Title	Page
1	Laboratory-Scale Aerosol Tunnel (LSAT)	8
2	Viable Sampling from LSAT into All-Glass Impingers (AGI-30)	8
3	Particle Size Distribution of Aerosolized Artificial Saliva Buffer	9

LIST OF TABLES

Table	Title	Page
1	LSAT Port Correlation.....	9
2	Challenge Filtering Facepiece Respirators with 0.8- μ m beads—Raw Data	10
3	Challenge Filtering Facepiece Respirators with 0.8 μ m beads—Percent Reduction	10
4	Challenge Filtering Facepiece Respirators with Viable H1N1 Influenza—Raw Data...	11
5	Challenge Filtering Facepiece Respirators with Viable H1N1 Influenza—Percent Reduction	11

OVERVIEW

H1N1 is a strain of Influenza A virus belonging to the *Orthomyxoviridae* family¹. The virus is a single-stranded RNA virus containing a nucleocapsid and envelope that is 80–120 nm in diameter¹. In March and April 2009 a new flu virus of swine origin was first detected in Mexico and the United States. According to the CDC, since the outbreak began in the United States, an increasing number of U.S. states have reported cases of novel H1N1 influenza with associated hospitalizations and deaths. By 3 June 2009 all 50 states in the United States, the District of Columbia and Puerto Rico were reporting cases of novel H1N1 infection. Current CDC interim recommendations to reduce person-to-person H1N1 virus transmission include the use of respiratory protection devices in some situations. Furthermore, in the past decade, respirators have become commonplace among healthcare workers who aim to protect themselves against any number of respiratory pathogens. Research by NIOSH, AFRL and others has demonstrated that filters such as those used in NIOSH-approved filtering facepiece respirators are capable of capturing bioaerosols as predicted by filtration theory and through comparison with inert (non-biological) aerosols. However, continued stakeholder requests for filtration testing with droplet nuclei containing virus particles similar to the novel H1N1 influenza strain seen in the 2009 outbreak revealed an urgent need to conduct additional research to further validate the filtration performance of NIOSH-approved filtering facepiece respirators. The results of this study will be used by NIOSH, CDC, and other national and international public health agencies to support existing recommendations or provide updated guidance on the use of respiratory protection devices to reduce person-to-person transmission of the novel H1N1 virus.

EXECUTIVE SUMMARY

The 3M1860s (N95) and 3M 8293 (P100) NIOSH-approved filtering facepiece respirators (FFRs) were challenged with aerosolized particles of H1N1 influenza to determine the amount of viable influenza virus that penetrates each device. The test was conducted at the NIOSH-recommended flowrate of 85 LPM using guidance provided by a Department of Defense test standard developed for challenging air purification devices with viable microbial aerosols. The count mode diameter (CMD) particle size of the challenge aerosol was ~0.8 µm, which was created by aerosolizing H1N1 influenza virus in an artificial saliva buffer using the Laboratory-Scale Aerosol Tunnel (LSAT). In addition to the H1N1 challenge, each FFR was also challenged with 0.8-µm inert beads. The N95 FFR ($n = 3$) removed > 99% of the viable H1N1 from the air stream and the P100 ($n = 3$) removed > 99.99% of viable H1N1 from the airstream. The percent reduction in particle counts measured for each FFR using the 0.8-µm bead challenge were equivalent to the H1N1 percent reduction values. These data demonstrate that the N95 and P100 FFR will reduce viable H1N1 aerosol from the airstream at greater than or equal to their rated value.

¹ Universal Virus Database of the International Committee on Taxonomy of Viruses (ICTVdB). <http://www.ncbi.nlm.nih.gov/ICTVdb/Ictv/fr-index.htm>

1.0 MATERIALS AND METHODS

1.1 Preparation of H1N1 Virus

Influenza A/PR/8/34 VR-1469 (ATCC VR-95) was propagated in embryonic chicken eggs using standard protocols (1). Virus titers were determined using a tissue culture infectious dose assay (TCID₅₀) in Madin–Darby canine kidney cells (MDCK; ATCC CCL-34) with cell culture techniques approved by the World Health Organization (1).

1.2 Laboratory-Scale Aerosol Tunnel (LSAT)

The LSAT was designed to challenge air purification systems with viable microbial aerosols and is ideally suited for this study (Figure 1). A complete description, operation instructions, validation report, and accompanying test protocols have been previously described (2). Briefly, the LSAT is composed of 10-cm diameter stainless steel sanitary fittings and a 15-cm diameter filter holder is used to accommodate the FFR. The biological aerosol is generated using a six-jet Collison nebulizer (BGI Inc., Waltham, Mass.). Dilution air, which is conditioned by passing the air through a humidifier, is added through two porous tube diluters (Mott corporation, Farmington, Ct.), one located upstream and the other downstream of the charge neutralizer. The Kr-85 charge neutralizer (TSI Incorporated, Shoreview, Minn.) is required to neutralize charges created on particles during aerosolization. Overflow valves are located upstream of the expansion chamber to divert aerosol away from the test specimen. The expansion duct contains three mixing screens which create turbulent flow and allow the aerosol to mix prior to being exposed to the test specimen. Isokinetic sampling ports located upstream and downstream of the sample allow for viable sampling of microbial agents from the airstream and can also be used with traditional particle counters.

A critical mechanical operational element of the LSAT is to ensure the upstream and downstream sampling ports collect the same volume of particles. To validate the performance of the sampling ports, 30 mL of artificial saliva buffer (3) (0.42 g NaHCO₃, 0.04 g MgCl₂•7 H₂O, 0.13 g CaCl₂•H₂O, 7.70 mL 0.2 M KH₂PO₄, 12.3 mL 0.2 M K₂HPO₄, 0.11 g NH₄Cl, 0.19 g KSCN, 0.12 g (NH₂)₂CO, 0.88 g NaCl, 1.04 g KCl, 3.00 g mucin (Sigma–Aldrich, St. Louis, Mo., M1778), 1 L deionized water, pH 7) was placed in a six-jet Collison nebulizer (BGI Inc., Waltham, Mass.) and attached to the LSAT. Compressed air (30 psi) was added to the Collison nebulizer to start the aerosol flow. Dilution air was added to both porous tube diluters so that the total flow was 85 LPM.

The LSAT was run for 10 minutes then samples were taken alternately from the upstream and downstream ports using an Aerodynamic Particle Sizer (APS, TSI Incorporated, Shoreview, Minn.) Three upstream and three downstream measurements were collected. The port correlation was repeated three additional times using an aerosol of 0.8-µm polystyrene latex beads (PSL) (Thermo Scientific, Waltham, Mass.).

1.3 Preparation of Filtering Facepiece Respirators

Three replicate samples of 3M 1860s (N95) and 3M 8293 (P100) FFRs were glue sealed into 6-inch sample holders. The filters were leak checked by challenging each filter with an aerosol composed of 0.8- μ m PSL beads as described above.

1.4 H1N1 Filtration Studies

Prior to each test the LSAT was flushed with HEPA-purified air for 30 minutes, after which a minimum of three APS measurements were taken on the upstream and downstream port. A leak-checked FFR was loaded into the LSAT using sanitary compression seal fittings. The six-jet Collison nebulizer, containing 1 mL of H1N1 influenza virus ($8.6 \log_{10} \text{TCID}_{50}$ per mL) suspension diluted into 30 mL of mucin buffer, was attached to the LSAT. The LSAT was configured to direct the aerosol to the overflow and not to the FFR. Compressed air (30 psi) was applied to the Collison nebulizer and dilution air was added to both porous tube diluters so the total flow was 85 LPM. The system was operated for 10 minutes to bring the nebulizer to steady state, whereupon the LSAT overflow valves were reconfigured to allow the viral aerosol to be exposed to the FFR sample for an additional 5 minutes. Viable sampling of the aerosol into upstream and downstream ports was initiated by connecting All-Glass Impingers (AGI-30, Ace Glass, Vineland, N.J.) containing 20 mL of serum-free Eagle's Minimum Essential Medium (sf-EMEM, Hyclone Laboratories Inc, Logan, Utah) supplemented with 1 % pen/strep and 1% L-glutamine (Sigma Aldrich, St. Louis, Mo.) to the LSAT. The AGI-30s were directly attached to the isokinetic sampling ports on the LSAT to minimize particle loss (Figure 2). Sampling was started by opening the valve on the isokinetic sampling port, followed by applying vacuum to the AGI-30, which sampled at ~12.5 LPM. After 5 minutes the isokinetic sampling port was closed, the vacuum was turned off and the AGI-30 was placed on ice until viable plating was performed. A total of six samples (three upstream and three downstream, alternately sampled) were collected for each FFR. The test was repeated five times to completely account for all six FFRs.

1.5 Viable Plating of H1N1 Influenza Virus

The sf-EMEM buffer in the AGI-30s was evaluated for viable H1N1 using a TCID_{50} assay in MDCK cells as described above. The upstream samples were serially diluted 1/10 to 10^{-6} ; The 10^{-2} – 10^{-6} dilutions were plated in quadruplicate into 24-well tissue culture plates containing a confluent lawn of MDCK cells. The downstream samples for the N95 FFR were serially diluted to 10^{-4} and all stages of the dilutions were plated in quadruplicate. The downstream P100 samples were serially diluted to 10^{-2} , and the 10^{-1} and 10^{-2} samples were plated in quadruplicate. In addition the entire volume of the neat sample for the P100 FFRs was also plated to maximize sensitivity. The plates were incubated for 4 days at 5% CO_2 /37 °C prior to reading cytopathic effects.

1.6 Data Analysis

Sampling Port Correlation Factor (CF)—Port correlation with 0.8- μm bead studies used the APS particle bins ranging in size from 0.723–0.925 μm . The count in each bin was summed to yield the total particle concentration for each sample. The port correlation for the mucin buffer used the particle concentration that represented the entire measurement range of the APS (0.5–20 μm). The port correlation was determined by calculating the ratio of the average downstream counts to the average upstream counts (see appendix III).

Filtration Efficiency—Upstream and downstream measurements for the 0.8- μm bead study were collected using the 0.723–0.925 μm bins on the APS as described above. Viable virus collected in the upstream and downstream AGI-30s (viable virus per mL of extract) were determined using the Spearman–Karber formula (4). Equation 1 was used to determine the total amount of virus recovered from the each sample (20-mL impinger volume). Viable filtration efficiency (VFE) of the FFRs was determined using equation 2. Particle filtration efficiency (PFE) of the sample was determined using equation 3. For further clarification see appendices II and IV. Prism 5 software (GraphPad Inc., La Jolla, Calif.) was used to determine 95% confidence intervals for the filtration efficiency

Equation 1: $\text{Virus concentration/sample}^* = L_s = 10^{[L + \log(V)]}$

Where : L = Viable H1N1 expressed in units of $\log_{10}\text{TCID}_{50}/\text{mL}$
 V = sample volume

* If no viable viruses are present ($L = -\infty$) then L_s will be 0.

Equation 2:
$$\text{VFE} = \left(\sum_{i=1}^n [1 - (DL_s/UL_s)/CF] \times 100\% \right) / n$$

Where: DL_s = downstream $\log_{10}\text{TCID}_{50}$
 UL_s = upstream $\log_{10}\text{TCID}_{50}$
 CF = correlation factor
 n = number of determinations

Equation 3:
$$\text{PFE} = \left(\sum_{i=1}^n [1 - (D/U)/CF] \times 100\% \right) / n$$

Where: U = upstream particle concentration
 D = downstream particle concentration

Statistical analysis of penetration data—A two-tailed unpaired t -test was used to compare the nonviable (0.8- μm bead) and viable (H1N1 influenza) filtration data for the three replicates of the N95 and P100 FFRs. The average PFE and VFE values for each FFR were loaded into Prism 5 software (GraphPad Inc., La Jolla, Calif.) to perform the t -test at the 95% confidence intervals.

2.0 RESULTS

The upstream and downstream ports of the LSAT were demonstrated to be > 99% similar for sampling particles derived from both mucin buffer and 0.8- μm beads (Table 1). The particle size distributions of the mucin buffer sampled from the upstream and downstream ports were also identical (Figure 3).

The 0.8- μm bead challenge of each FFR indicated the glue seal was adequate to prevent leakage of particles around the FFR (Tables 2 and 3). The N95 FFRs removed 99.86% of the beads and the P100 FFR removed 99.999% of the beads from the air stream. Viable challenge results correlated well with the bead penetration data: The N95 FFRs reduced the airborne challenge of viable influenza by > 99% the P100 FFRs achieved > 99.99% removal (Tables 4 and 5). The bead and H1N1 data for both the N95 and P100 FFRs were found not to be statistically different ($p = 0.06$ and $p = 0.52$, respectively).

3.0 DISCUSSION

The data clearly show that both the N95 and the P100 FFRs are effective at removing viable H1N1 particles from the airstream. The filtration efficiency for both FFRs exceeded their rating, as expected for the particle size used for this study—the FFR rating is based on penetration by the most-penetrating particle size ($\sim 0.3 \mu\text{m}$). The particles used for this study had a CMD centered near $0.8 \mu\text{m}$, so their filtration efficiency was higher. As expected the P100 FFR provided better capture of both viable H1N1 and inert particles than the N95 FFR. The N95 FFR did allow significant penetration by H1N1 influenza but this does not suggest the device is inadequate for protecting users from airborne transmission of influenza. To perform the aerosol test the challenge concentration of influenza is intentionally increased to levels higher than would be expected in a normal infectious disease setting—the average of $3.76 \log_{10} \text{TCID}_{50}$ per liter of air used in this study far exceeds values recorded for airborne influenza concentrations in hospital settings (5).

Because the environment in which the test is performed will influence the removal efficiency of the FFR, conditions were carefully selected based on the guidance provided in the test method (2). The critical conditions are flowrate and particle size. The NIOSH standard test rate of 85 LPM was used as the flowrate for all tests performed. The 0.8- μm particle size was selected to simulate the size of particles generated by a human cough. This was a compromise among the varying particle sizes reported to be exhaled by humans (6–13). We chose to focus on particles produced during coughing as this is a clinical symptom of influenza. Yang *et al.*, (14) studied the particle distribution produced by coughs from healthy human volunteers and determined that 82% of droplet nuclei generated by coughs fell inside the particle size window of $0.74\text{--}2.12 \mu\text{m}$. The particle size distribution used for this test had CMD centered on $\sim 0.8 \mu\text{m}$, which was produced by delivering the virus in artificial saliva. While it can be argued that other particle sizes and/or solutions could be used, we consider these particles representative of human respiratory secretions. The same particle size is also used in an ASTM method developed to load surfaces with H1N1 particles that are representative of human respiratory secretions (15).

A comparison of the viable H1N1 penetration and the nonviable bead penetration demonstrates that both provide equivalent filtration efficiency. Thus it can be concluded that the presence of infectious microorganisms does not influence filtration efficiency of the FFR. This same phenomenon has been demonstrated by other researchers using different microbial agents (14, 15). This is an important consideration because experiments aerosolizing highly infectious microbial agents such as influenza are expensive and difficult to perform. Undoubtedly it is comforting for healthcare workers and others who use FFRs to see data demonstrating that FFRs filter out viable threat agents. However, filtration theory is very well understood (18) and the applicability of viable filtration data seems to fill an occupational, rather than a scientific niche. Better education of FFR users is needed to help them understand that filtration is solely based on physics and not whether the particle carries a pathogen.

Another caveat of these data that must be considered is that only the performance of the filtration media was evaluated. To achieve expected levels of respiratory protection by a device, a good fit must also be achieved. It is imperative that an OSHA-regulated FFR fit test program be implemented by any organization with a respiratory protection program.

4.0 SUMMARY

N95 and P100 FFRs were shown to be effective at removing viable H1N1 from an airstream. The P100 provided filtration efficiency two orders of magnitude higher than the N95 FFR. The performance of both devices for filtering H1N1 influenza particles was expected based on filtration theory. The study evaluated only the filtration performance of the media, and a proper fit is required to achieve adequate performance of the device. However, with a proper fit, both devices should reduce inhalation exposures to airborne H1N1 aerosols.

5.0 REFERENCES

1. WHO manual on animal influenza diagnosis and surveillance. 2002. World Health Organization website: http://www.who.int/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5.pdf/.
2. Foarde K, Heimbuch BK, Maxwell A, VanOsdell D. 2009. Method for evaluating air purification technologies for collective protection using viable microbial aerosols. Test Operating Procedure (TOP) under the Army Test and Evaluation Command (ATEC). Edgewood Chemical and Biological Center, Edgewood, Md. *in press*.
3. Aps JKM and Martens LC. 2005. Review: The physiology of saliva and transfer of drugs into saliva. *Forensic Sci. Int.*; 150(2):119–131
4. Finney DJ. 1964. Statistical methods in biological assays. 2nd ed. New York: Hafner Publishing, New York, N.Y.
5. Blachere FM, Lindsley WG, Pearce TA, Anderson SE, Fisher M, Khakoo R, Meade BJ, Lander O, Davis S, Thewlis RE, Celik I, Chen BT, and Beezhold DH. 2009.

Measurement of Airborne Influenza Virus in a Hospital Emergency Department. *Clinical Infectious Diseases*; 48:438-440.

6. Hall C B. 2007. The Spread of Influenza and Other Respiratory Viruses: Complexities and Conjectures. *Healthcare Epidemiology*. 45:353–359.
7. Tang JW, Li Y, Eames I, Chan PKS, and Ridgway GL. 2006. Factors involved in the aerosol transmission of infection and control of ventilation in healthcare premises. *J. Hospital Infection* 64:110–114.
8. Tellier R. 2006. Review of Aerosol Transmission of Influenza A Virus. *Emerging Infectious Diseases* 12:1657–1662.
9. Knight V. 1980. Viruses as Agents of Airborne Contagion. *Ann. N.Y. Acad. Sci.* 353:147–156.
10. Papieneni RS, and Rosenthal FS. 1997. The Size Distribution of Droplets in the Exhaled Breath of Healthy Human Subjects. *J. Aerosol Med.* 10:105–116.
11. Riley R L. 1961. Droplets, Droplet Nuclei, and Dust. In F. O'Grady (ed.), *Airborne infection: transmission and control*. Macmillan, New York, New York.
12. Zhao B, Zhang Z, and Li X. 2005. Numerical study of the transport of droplets or particles generated by respiratory system indoors. *Bldg. Environment* 40:1032–1039.
13. Zhu S, Kato S, and Yang J-H. 2006. Study on transport characteristics of saliva droplets produced by coughing in a calm indoor environment. *Bldg. Environment* 41:1691–1702.
14. Yang S, Lee GWM, Chen C-M, Wu C-C, and Yu K-P. 2007. The Size and concentration of Droplets Generated by coughing in Human Subjects. *Journal of Aerosol Medicine* 20:484-494.
15. WK19997: Standard test method for effectiveness of decontamination of air-permeable materials challenged with biological aerosols containing human pathogenic viruses, American Society for Testing and Materials (ASTM) International, 100 Barr Harbor Drive, West Conshohocken, PA 19428-2959. In press.
16. Gardner PD, Richardson AW, Eshbaugh JP, and Hofacre KC. 2006. Respirator Filter Efficiency Testing Against Particulate and Biological Aerosols Under Moderate to High Flow Rates, ECBC-CR-085. Edgewood Chemical and Biological Center, U.S. Army Research Development and Engineering Command, Aberdeen Proving Ground, MD 21010-5423.
17. Heimbuch BK, Wu C-Y, Hodge J, Wander JD. 2007. Viral Penetration of HEPA Filters. Defense Technical Information Center (DTIC). Air Force Research Laboratories, Report number: AFRL-ML-TY-TP-2007-4512.
18. Hinds W C. 1999. *Aerosol Technology Properties, Behavior, and Measurement of Airborne particles*, 2nd ed. John Wiley and Sons Inc., New York, New York.




Figure 1. The Laboratory-Scale Aerosol Tunnel (LSAT)




Figure 2. Viable sampling from the LSAT into an AGI-30




Figure 3. Size Distribution of Artificial Saliva Buffer Aerosolized in LSAT Using the Aerodynamic Particle Sizer Data

Table 1. LSAT Upstream–Downstream Sampling Port Correlation

Aerosol	Particle Concentration (dN/dlogp, cm ³)		Correlation Factor
	Upstream Port	Downstream Port	
Artificial Saliva Buffer	$7.38 \times 10^3 \pm 3.46 \times 10^2$	$7.31 \times 10^3 \pm 1.06 \times 10^2$	1.01
0.8-μm Beads	$6.20 \times 10^3 \pm 1.57 \times 10^2$	$6.25 \times 10^3 \pm 1.31 \times 10^2$	0.99
0.8-μm Beads	$1.00 \times 10^4 \pm 3.26 \times 10^2$	$1.00 \times 10^4 \pm 3.60 \times 10^2$	1.00
0.8-μm Beads	$6.46 \times 10^3 \pm 8.58 \times 10^1$	$6.45 \times 10^3 \pm 1.36 \times 10^2$	1.00
Average			1.00

Table 2. Challenge of Filtering Facepiece Respirators with 0.8- μ m Beads (dN/dlogp, cm³ for size range 0.723–0.965 μ m)

3M 1860s (N95)	Test 1		Test 2		Test 3	
	Upstream	Downstream	Upstream	Downstream	Upstream	Downstream
Sample #1	7.16 x 10 ³	11.17	7.67 x 10 ³	6.56	8.09 x 10 ³	5.63
Sample #2	8.31 x 10 ³	19.01	8.44 x 10 ³	22.59	8.56 x 10 ³	24.99
Sample #3	1.11 x 10 ⁴	9.57	1.12 x 10 ⁴	10.30	1.16 x 10 ⁴	9.47

3M 8293 (P100)	Test 1		Test 2		Test 3	
	Upstream	Downstream	Upstream	Downstream	Upstream	Downstream
Sample #1	1.70 x 10 ⁴	ND*	1.76 x 10 ⁴	ND	1.83 x 10 ⁴	ND
Sample #2	1.45 x 10 ⁴	0.10	1.48 x 10 ⁴	0.32	1.63 x 10 ⁴	0.48
Sample #3	4.71 x 10 ⁴	ND	5.55 x 10 ⁴	ND	No data	ND

*No particles detected

Table 3. Challenge of Filtering Facepiece Respirators with 0.8- μ m Beads—Percent Reduction

3M 1860s (N95)	Test 1	Test 2	Test 3	Average	L 95% CI	U 95% CI
Sample #1	99.84%	99.91%	99.93%	99.89%	99.78%	99.99%
Sample #2	99.77%	99.73%	99.71%	99.74%	99.66%	99.81%
Sample #3	99.91%	99.91%	99.92%	99.91%	99.90%	99.93%

3M 8293 (P100)	Test 1	Test 2	Test 3	Average	L 95% CI	U 95% CI
Sample #1	> 99.999%	> 99.999%	> 99.999%	> 99.999%	-----*	-----
Sample #2	99.999%	99.998%	99.997%	99.998%	99.996%	99.999%
Sample #3	> 99.999%	> 99.999%	> 99.999%	> 99.999%	-----	-----

* Statistical analysis cannot be completed when replicate data have identical values

Table 4. Challenge of Filtering Facepiece Respirators with H1N1 influenza
(Log₁₀TCID₅₀ per sample)

3M 1860s (N95)	Test 1		Test 2		Test 3	
	Upstream	Downstream	Upstream	Downstream	Upstream	Downstream
Sample #1	5.6	3.6	5.6	3.3	5.6	3.6
Sample #2	5.3	3.3	5.05	3.3	5.3	2.8
Sample #3	5.55	2.8	6.05	3.3	5.8	3.55

3M 8293 (P100)	Test 1		Test 2		Test 3	
	Upstream	Downstream	Upstream	Downstream	Upstream	Downstream
Sample #1	5.8	ND	5.3	ND	5.3	0.88
Sample #2	5.55	0.97	5.3	ND	5.55	ND
Sample #3	5.55	ND	5.55	ND	5.55	ND

*No viable virus detected

Table 5. Challenge of Filtering Facepiece Respirators with H1N1 influenza—Percent Reduction

3M 1860s (N95)	Sample 1	Sample 2	Sample 3	Average	L 95% CI	U 95% CI
Sample #1	99.00%	99.44%	99.00%	99.15%	98.52%	99.77%
Sample #2	99.00%	98.22%	99.68%	98.97%	97.15%	99.999%
Sample #3	99.82%	99.82%	99.44%	99.69%	99.17%	99.999%

3M 8293 (P100)	Sample 1	Sample 2	Sample 3	Average	L 95% CI	U 95% CI
Sample #1	> 99.999%	> 99.999%	99.996%	[†] 99.998%	99.994%	99.999%
Sample #2	99.997%	> 99.999%	> 99.999%	[†] 99.998%	99.995%	99.999%
Sample #3	> 99.999%	> 99.999%	> 99.999%	> 99.999%	-----*	-----

*Statistical analysis cannot be completed when replicate data have identical values

[†] Detection limit of 99.999% was used to calculate averages for samples that had no detectable virus

Appendix I – H1N1 influenza aerosol run forms

Test Samples:						
Sample:	N95 FFR: 3M1860s FFR - #1		Lot # :	17086		
Dimension:	Full device, glue sealed into 6" circular LSAT mount					
Test stand:						
Laboratory Scale Aerosol Tunnel						
Aerosolizer:	6-jet Collison nebulizer; only one used					
Biological collector:	AGI30 impingers (1 per port)					
Microorganism:						
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)						
Preparation method Embryonic eggs according to WHO protocol						
Reagents:						
Nebulization fluid:	mucin buffer					
Collection buffer:	serum free EMEM					
Dilution buffer:	serum free EMEM					
Media:	EMEM supplemented with serum, pen/strep, and glutamine					
Experimental:						
Pressure drop:	Start:	.35 in water	Middle:	.4 in water	End:	.45 in water
Temperature	Start:	23.5 C	Middle:	23 C	End:	23 C
Humidity	Start:	32.9% RH	Middle:	34% RH	End:	33.9% RH
System flow rate:	85 SLPM					
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)						
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge:	3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM						
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM	
Challenge test sampling times for upstream and down stream collectors						
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		

Test Samples:						
Sample:	N95 FFR: 3M1860s FFR - #2		Lot # :	17086		
Dimension:	Full device, glue sealed into 6" circular LSAT mount					
Test stand:						
Laboratory Scale Aerosol Tunnel						
Aerosolizer:	6-jet Collison nebulizer; only one used					
Biological collector:	AGI30 impingers (1 per port)					
Microorganism:						
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)						
Preparation method Embryonic eggs according to WHO protocol						
Reagents:						
Nebulization fluid:	mucin buffer					
Collection buffer:	serum free EMEM					
Dilution buffer:	serum free EMEM					
Media:	EMEM supplemented with serum, pen/strep, and glutamine					
Experimental:						
Pressure drop:	Start:	.4 in water	Middle:	.4 in water	End:	.45 in water
Temperature	Start:	24.1 C	Middle:	24 C	End:	23.9 C
Humidity	Start:	31.6% RH	Middle:	31.9% RH	End:	32% RH
System flow rate:	85 SLPM					
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)						
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge:	3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM						
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM	
<u>Challenge test sampling times for upstream and down stream collectors</u>						
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		

Test Samples:						
Sample:	N95 FFR: 3M1860s FFR - #3		Lot # :	17086		
Dimension:	Full device, glue sealed into 6" circular LSAT mount					
Test stand:						
Laboratory Scale Aerosol Tunnel						
Aerosolizer:	6-jet Collision nebulizer; only one used					
Biological collector:	AGI30 impingers (1 per port)					
Microorganism:						
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)						
Preparation method Embryonic eggs according to WHO protocol						
Reagents:						
Nebulization fluid:	mucin buffer					
Collection buffer:	serum free EMEM					
Dilution buffer:	serum free EMEM					
Media:	EMEM supplemented with serum, pen/strep, and glutamine					
Experimental:						
Pressure drop:	Start:	.35 in water	Middle:	.4 in water	End:	.45 in water
Temperature	Start:	24.2 C	Middle:	23.9 C	End:	23.9 C
Humidity	Start:	31.6% RH	Middle:	31.9% RH	End:	32% RH
System flow rate:	85 SLPM					
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)						
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge:	3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM						
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM	
<u>Challenge test sampling times for upstream and down stream collectors</u>						
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS		
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30		

Test Samples:					
Sample:	P100 FFR: 3M 8293 FFR - #1		Lot # :	19135	
Dimension:	Full device, glue sealed into 6" circular LSAT mount				
Test stand:					
Laboratory Scale Aerosol Tunnel					
Aerosolizer:	6-jet Collision nebulizer; only one used				
Biological collector:	AGI30 impingers (1 per port)				
Microorganism:					
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)					
Preparation method Embryonic eggs according to WHO protocol					
Reagents:					
Nebulization fluid:	mucin buffer				
Collection buffer:	serum free EMEM				
Dilution buffer:	serum free EMEM				
Media:	EMEM supplemented with serum, pen/strep, and glutamine				
Experimental:					
Pressure drop:	Start:	.55 in water	Middle:	.55 in water	End: .6 in water
Temperature	Start:	22.7 C	Middle:	22.5 C	End: 22.7 C
Humidity	Start:	26.3% RH	Middle:	23.8% RH	End: 23.6% RH
System flow rate:	85 SLPM				
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)					
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge: 3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM					
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM
<u>Challenge test sampling times for upstream and down stream collectors</u>					
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	

Test Samples:					
Sample:	P100 FFR: 3M 8293 FFR - #2		Lot # :	19135	
Dimension:	Full device, glue sealed into 6" circular LSAT mount				
Test stand:					
Laboratory Scale Aerosol Tunnel					
Aerosolizer:	6-jet Collison nebulizer; only one used				
Biological collector:	AGI30 impingers (1 per port)				
Microorganism:					
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)					
Preparation method Embryonic eggs according to WHO protocol					
Reagents:					
Nebulization fluid:	mucin buffer				
Collection buffer:	serum free EMEM				
Dilution buffer:	serum free EMEM				
Media:	EMEM supplemented with serum, pen/strep, and glutamine				
Experimental:					
Pressure drop:	Start:	.6 in water	Middle:	.65 in water	End: .65 in water
Temperature	Start:	23.3 C	Middle:	23.4 C	End: 23.4 C
Humidity	Start:	25.8% RH	Middle:	23.4% RH	End: 25.3% RH
System flow rate:	85 SLPM				
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)					
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge: 3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM					
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM
<u>Challenge test sampling times for upstream and down stream collectors</u>					
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	

Test Samples:					
Sample:	P100 FFR: 3M 8293 FFR - #3		Lot # :	19135	
Dimension:	Full device, glue sealed into 6" circular LSAT mount				
Test stand:					
Laboratory Scale Aerosol Tunnel					
Aerosolizer:	6-jet Collision nebulizer; only one used				
Biological collector:	AGI30 impingers (1 per port) containing 20 mL of collection buffer				
Microorganism:					
Genus species & ATCC number : H1N1 Influenza A/PR/8/34 VR-1469 (ATCC VR-95H1N1)					
Preparation method Embryonic eggs according to WHO protocol					
Reagents:					
Nebulization fluid: mucin buffer					
Collection buffer: serum free EMEM					
Dilution buffer: serum free EMEM					
Media: EMEM supplemented with serum, pen/strep, and glutamine					
Experimental:					
Pressure drop:	Start:	.55 in water	Middle:	.55 in water	End: .6 in water
Temperature	Start:	24.9 C	Middle:	24.9 C	End: 25 C
Humidity	Start:	26.3% RH	Middle:	26.3% RH	End: 26% RH
System flow rate: 85 SLPM					
Prequilibration time prior to sampling: 15 minutes (10 minutes to overflow and 5 minutes to sample)					
Number of Replicates:	Background	1 per port	100% Correlation:	1 per port	Challenge: 3 per port
Flow rates for biological collectors: AGI30s sampled at ~12.5 LPM					
Background	5 SLPM Used APS	100% Correlation:	5 SLPM Used APS	Challenge	~12.5 SLPM
<u>Challenge test sampling times for upstream and down stream collectors</u>					
Background:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Correlation:	Upstream:	3 min/APS	Downstream:	3 min/APS	
Challenge #1:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #2:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	
Challenge #3:	Upstream:	5 min/AGI-30	Downstream:	5 min/AGI-30	

Sample:	3M 1860S #1																												
Plating Results:																													
Dilution	Upstream 1				Upstream 2				Upstream 3				Dilution				Downstream 1				Downstream 2				Downstream 3				
-2	X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
-3	X	X	X	X	X	X	X	X	X	X	X	X	-1	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X
-4	X	X	X	o	X	o	X	o	o	X	X	o	-2	X	X	o	o	X	X	o	o	X	X	o	o	X	X	o	X
-5	o	o	o	o	X	o	o	o	o	X	o	o	-3	o	X	o	o	o	o	o	o	o	o	o	o	o	o	o	o
-6	o	o	o	o	o	o	o	o	o	o	o	o	-4	o	o	o	o	o	o	o	o	o	o	o	o	o	o	o	o
x = cytopathic effect, o = healthy cells																													
Data:																													
LOG TCID ₅₀ /mL (<i>L</i>)	4.25				4.25				4.25								2.25				2.00				2.25				
Sample volume (<i>V</i>)	20				20				20								20				20				20				
Log <i>V</i>	1.30				1.30				1.30								1.30				1.30				1.30				
Log titer per sample	5.6				5.6				5.6								3.6				3.3				3.6				
	<i>ULs1</i>				<i>ULs2</i>				<i>ULs3</i>								<i>DLs1</i>				<i>DLs2</i>				<i>DLs3</i>				
TCID ₅₀ infectious dose units (<i>Ls</i>)	3.56E+05				3.56E+05				3.56E+05								3.56E+03				2.00E+03				3.56E+03				
Average	3.56E+05																3.04E+03												
stdev	0																0.14												
Percent Reduction (VRE)																													
1-(<i>DLs1 ÷ ULs1 ÷ CF*</i>) X 100%	99.000%																												
1-(<i>DLs2 ÷ ULs2 ÷ CF*</i>) X 100%	99.438%																												
1-(<i>DLs3 ÷ ULs3 ÷ CF*</i>) X 100%	99.000%																												
VRE	99.146%																												
*CF (Correlation Factor) = 1																													
Aerosol concentration (Log titer per Liter of air):									3.76																				

Sample:	3M 1860S #2																								
Plating Results:																									
Dilution	Upstream 1				Upstream 2				Upstream 3				Dilution	Downstream 1				Downstream 2				Downstream 3			
-2	X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	X	X	X	X	X	X	X	X	X			
-3	X	X	X	X	X	X	X	X	X	X	X	X	-1	X	X	X	X	X	X	X	X	X			
-4	o	X	X	o	o	o	o	X	o	X	X	o	-2	X	X	o	o	X	X	o	o	o			
-5	o	o	o	o	o	X	o	o	o	o	o	o	-3	o	o	o	o	o	o	o	o	o			
-6	o	o	o	o	o	o	o	o	o	o	o	o	-4	o	o	o	o	o	o	o	o	o			
x = cytopathic effect, o = healthy cells																									
Data:																									
LOG TCID ₅₀ /mL (L)	4.00				3.75				4.00				2.00				2.00				1.50				
Sample volume (V)	20				20				20				20				20				20				
Log V	1.30				1.30				1.30				1.30				1.30				1.30				
Log titer per sample	5.3				5.1				5.3				3.3				3.3				2.8				
	ULs1				ULs2				ULs3				DLs1				DLs2				DLs3				
TCID ₅₀ infectious dose units (Ls)	2.00E+05				1.12E+05				2.00E+05				2.00E+03				2.00E+03				6.32E+02				
Average	1.71E+05												1.54E+03												
stdev	0.144337567												0.29												
Percent Reduction (VRE)																									
1-(DLs1 ÷ ULs1 ÷ CF*) X 100%	99.000%																								
1-(DLs2 ÷ ULs2 ÷ CF*) X 100%	98.222%																								
1-(DLs3 ÷ ULs3 ÷ CF*) X 100%	99.684%																								
VRE	98.968%																								
*CF (Correlation Factor) = 1																									
Aerosol concentration (Log titer per Liter of air):																									
3.44																									

Sample:	3M 8293 #2																								
Plating Results:																									
Dilution	Upstream 1				Upstream 2				Upstream 3				Dilution	Downstream 1				Downstream 2				Downstream 3			
-2	X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	o	X	X	o	o	o	o	o	o	o		
-3	X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	o	o	o	o	o	o	o	o	o	o		
-4	X	o	X	X	o	o	o	X	X	X	o	X	Undiluted	o	o	o	o	o	o	o	o	o	o		
-5	o	o	o	o	o	X	o	X	o	o	o	o	-1	o	o	o	o	o	o	o	o	o	o		
-6	o	o	o	o	X	o	o	o	o	o	o	o	-2	o	o	o	o	o	o	o	o	o	o		
x = cytopathic effect, o = healthy cells																									
Data:																									
LOG TCID ₅₀ /mL (L)	4.25				4.00				4.25				-0.33				0.00				0.00				
Sample volume (V)	20				20				20				20				20				20				
Log V	1.30				1.30				1.30				1.30				1.30				1.30				
Log titer per sample	5.6				5.3				5.6				1.0				1.3				1.3				
	ULs1				ULs2				ULs3				DLs1				DLs2				DLs3				
TCID ₅₀ infectious dose units (Ls)	3.56E+05				2.00E+05				3.56E+05				9.28E+00				0.00E+00				0.00E+00				
Average	3.04E+05												3.09E+00												
stdev	0.144337567												0.19												
Percent Reduction (VRE)																									
1-(DLs1 ÷ ULs1 ÷ CF*) X 100%	99.997%																								
1-(DLs2 ÷ ULs2 ÷ CF*) X 100%	99.999%																								
1-(DLs3 ÷ ULs3 ÷ CF*) X 100%	99.999%																								
VRE	99.998%																								
*CF (Correlation Factor) = 1																									
Aerosol concentration (Log titer per Liter of air):																									
3.69																									

Sample:		3M 8293 #3																									
Plating Results:																											
Dilution		Upstream 1				Upstream 2				Upstream 3				Dilution		Downstream 1				Downstream 2				Downstream 3			
-2		X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	o	o	o	o	o	o	o	o	o	o			
-3		X	X	X	X	X	X	X	X	X	X	X	X	Undiluted	o	o	o	o	o	o	o	o	o	o			
-4		o	X	X	X	X								Undiluted	o	o	o	o	o	o	o	o	o	o			
-5		o	o	o	o	o	o	o	o	o	o	o	o	-1	o	o	o	o	o	o	o	o	o	o			
-6		o	o	o	o	o	o	o	o	o	o	o	o	-2	o	o	o	o	o	o	o	o	o	o			
x = cytopathic effect, o = healthy cells																											
Data:																											
LOG TCID ₅₀ /mL (L)		4.25				4.25				4.00						0.00				0.00				0.00			
Sample volume (V)		20				20				20						20				20				20			
Log V		1.30				1.30				1.30						1.30				1.30				1.30			
Log titer per sample		5.6				5.6				5.3						1.3				1.3				1.3			
		ULs1				ULs2				ULs3						DLs1				DLs2				DLs3			
TCID ₅₀ infectious dose units (Ls)		3.56E+05				3.56E+05				2.00E+05						0.00E+00				0.00E+00				0.00E+00			
Average		3.04E+05														0.00E+00											
stdev		0.144337567														0.00											
Percent Reduction (VRE)																											
1-(DLs1 ÷ ULs1 ÷ CF*) X 100%		99.999%																									
1-(DLs2 ÷ ULs2 ÷ CF*) X 100%		99.999%																									
1-(DLs3 ÷ ULs3 ÷ CF*) X 100%		99.999%																									
VRE		99.999%																									
*CF (Correlation Factor) = 1																											
Aerosol concentration (Log titer per Liter of air):																											
3.69																											

Appendix III – Port correlation data

Mucin Buffer Sampling Port Correlation			0.8 µm Beads #1 Port Correlation		
Samples	Upstream	Downstream	Samples	Upstream	Downstream
Particle concentration	6904.34	7156.13	Concentration (0.723 - 0.965)	6067.07	6114.21
Particle concentration	6999.7	7210.74	Concentration (0.723 - 0.965)	5972.61	6099.33
Particle concentration	7135.61	7226.24	Concentration (0.723 - 0.965)	6061.80	6098.57
Particle concentration	7229.31	7318.97	Concentration (0.723 - 0.965)	6235.45	6196.58
Particle concentration	7312.19	7335.87	Concentration (0.723 - 0.965)	6181.80	6251.20
Particle concentration	7312.86	7486.55	Concentration (0.723 - 0.965)	6193.70	6261.28
Particle concentration	7896.61	7430.33	Concentration (0.723 - 0.965)	6261.28	6421.90
Particle concentration	7892.69	7338.32	Concentration (0.723 - 0.965)	6308.22	6349.80
Particle concentration	7897.78	7265.31	Concentration (0.723 - 0.965)	6503.77	6426.02
Particle concentration	7464.38				
Particle concentration	7385.25		Average	6198.41	6246.54
Particle concentration	7153.51		Stdev	157.25	131.07
			CV	2.5%	2.1%
Average	7382.02	7307.61			
Stdev	346.23	105.88	Correlation Factor	0.99	1.01
CV	4.7%	1.4%			
Correlation Factor	1.01	0.99			

0.8 µm Beads #2 Port Correlation			0.8 µm Beads #3 Port Correlation		
Samples	Upstream	Downstream	Samples	Upstream	Downstream
Concentration (0.723 - 0.965)	9720.10	9437.19	Concentration (0.723 - 0.965)	6330.79	6158.86
Concentration (0.723 - 0.965)	9673.91	9600.57	Concentration (0.723 - 0.965)	6366.79	6300.36
Concentration (0.723 - 0.965)	9516.48	9709.92	Concentration (0.723 - 0.965)	6385.70	6436.58
Concentration (0.723 - 0.965)	9892.32	10168.11	Concentration (0.723 - 0.965)	6436.58	6529.41
Concentration (0.723 - 0.965)	10028.63	10207.19	Concentration (0.723 - 0.965)	6544.96	6537.57
Concentration (0.723 - 0.965)	10117.62	10185.11	Concentration (0.723 - 0.965)	6524.03	6536.32
Concentration (0.723 - 0.965)	10478.37	10423.00	Concentration (0.723 - 0.965)	6533.73	6540.16
Concentration (0.723 - 0.965)	10307.70	10361.08	Concentration (0.723 - 0.965)	6512.22	6551.10
Concentration (0.723 - 0.965)	10286.86	10278.80	Concentration (0.723 - 0.965)	6550.15	6494.94
Average	10002.44	10041.22	Average	6464.99	6453.92
Stdev	326.05	360.15	Stdev	85.76	136.47
CV	3.3%	3.6%	CV	1.3%	2.1%
Correlation Factor	1.00	1.00	Correlation Factor	1.00	1.00

Appendix IV – 0.8µm bead challenge data

3M 1860 #1 Particle Concentration (0.723 - 0.965µm bins)					3M 1860 #2 Particle Concentration (0.723 - 0.965µm bins)					
Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)	Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)	
Sample 1	7159.633	7161.01	10.94378	11.167778	Sample 1	8304.7	8307.16	19.2956401	19.00764607	
Sample 1	7125.168		13.53573		Sample 1	8317.369		18.047643		
Sample 1	7198.23		9.023824		Sample 1	8299.422		19.6796551		
Sample 2	7575.206	7666.70	6.623876	6.559873067	Sample 2	8427.956	8438.10	23.327493	22.59153233	
Sample 2	7606.697		7.0078581		Sample 2	8403.572		21.31161		
Sample 2	7818.182		6.0478851		Sample 2	8482.779		23.135494		
Sample 3	8112.409	8086.46	5.183895	5.631889033	Sample 3	8515.413	8559.51	24.1915001	24.99148473	
Sample 3	8002.591		5.663893		Sample 3	8629.18		24.3834901		
Sample 3	8144.382		6.0478791		Sample 3	8533.939		26.399464		
Percent Reduction					Percent Reduction					
1-(D1 ÷ U1 ÷ CF*) X 100%			99.84%		1-(D1 ÷ U1 ÷ CF*) X 100%			99.77%		
1-(D2 ÷ U2 ÷ CF*) X 100%			99.91%		1-(D2 ÷ U2 ÷ CF*) X 100%			99.73%		
1-(D3 ÷ U3 ÷ CF*) X 100%			99.93%		1-(D3 ÷ U3 ÷ CF*) X 100%			99.71%		
Average Percent Reduction			99.90%		Average Percent Reduction			99.74%		
*CF (Correlation Factor) = 1					*CF (Correlation Factor) = 1					
3M 1860 #3 Particle Concentration (0.723 - 0.965µm bins)										
Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)						
Sample 1	11048.51	11079.46	9.21582	9.5678134						
Sample 1	11054.08		8.639834							
Sample 1	11135.77		10.8477862							
Sample 2	11077.31	11218.46	10.271792	10.30379137						
Sample 2	11208.83		10.6557821							
Sample 2	11369.24		9.9838							
Sample 3	11547.51	11566.36	9.8878081	9.4718074						
Sample 3	11552.41		9.599796							
Sample 3	11599.16		8.9278181							
Percent Reduction										
1-(D1 ÷ U1 ÷ CF*) X 100%			99.91%							
1-(D2 ÷ U2 ÷ CF*) X 100%			99.91%							
1-(D3 ÷ U3 ÷ CF*) X 100%			99.92%							
Average Percent Reduction			99.91%							
*CF (Correlation Factor) = 1										

3M 8293 #1Particle Concentration (0.723 - 0.965µm bins)					3M 8293 #2Particle Concentration (0.723 - 0.965µm bins)					
Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)	Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)	
Sample 1	16954.99	17013.13	0	0	Sample 1	14396.74	14518.53	0	0.0959981	
Sample 1	17008.75		0		Sample 1	14364.67		0.1919962		
Sample 1	17075.66		0		Sample 1	14794.17		0.0959981		
Sample 2	17438.63	17593.28	0	0	Sample 2	14794.94	14755.99	0.287994	0.319993433	
Sample 2	17635.71		0		Sample 2	14727.06		0.3839922		
Sample 2	17705.51		0		Sample 2	14745.98		0.2879941		
Sample 3	18233.01	18313.20	0	0	Sample 3	16013.82	16324.18	0.7679842	0.479990233	
Sample 3	18369.61		0		Sample 3	16349.62		0.3839922		
Sample 3	18336.98		0		Sample 3	16609.11		0.2879943		
Percent Reduction					Percent Reduction					
1-(D1 ÷ U1 ÷ CF*) X 100%			99.999%		1-(D1 ÷ U1 ÷ CF*) X 100%			99.999%		
1-(D2 ÷ U2 ÷ CF*) X 100%			99.999%		1-(D2 ÷ U2 ÷ CF*) X 100%			99.998%		
1-(D3 ÷ U3 ÷ CF*) X 100%			99.999%		1-(D3 ÷ U3 ÷ CF*) X 100%			99.997%		
Average Percent Reduction			99.999%		Average Percent Reduction			99.998%		
*CF (Correlation Factor) = 1					*CF (Correlation Factor) = 1					
3M 8293 #3Particle Concentration (0.723 - 0.965µm bins)										
Samples	Upstream	Upstream Average (U)	Downstream	Downstream Average (D)						
Sample 1	45778.777	47075.52	0	0						
Sample 1	46754.683		0							
Sample 1	48693.114		0							
Sample 2	54694.245	55452.70	0	0						
Sample 2	55500.955		0							
Sample 2	56162.899		0							
Sample 3	No data	No data	0	0						
Sample 3	No data		0							
Sample 3	No data		0							
Percent Reduction										
1-(D1 ÷ U1 ÷ CF*) X 100%			99.999%							
1-(D2 ÷ U2 ÷ CF*) X 100%			99.999%							
1-(D3 ÷ U3 ÷ CF*) X 100%			99.999%							
Average Percent Reduction			99.999%							
*CF (Correlation Factor) = 1										

LIST OF ABBREVIATIONS, ACRONYMS AND SYMBOLS

AFRL	Air Force Research Laboratory
AGI-30	all-glass impinger with a 30-mL reservoir
APS	aerosol particle sizer
ASTM	ASTM International (formerly American Society for Testing Materials)
CDC	Center for Disease Control
CF	correlation factor (for sampling ports [p.4])
cm	centimeter
CMD	count mode diameter
CO ₂	carbon dioxide
FFR	filtering facepiece respirator
g	gram(s)
H1N1	a strain of influenza A identified by its hemagglutinin and neuraminidase
Kr-85	a radioactive isotope of krypton
L	liter
LPM	liters per minute
LSAT	Laboratory-Scale Aerosol Tunnel
MDCK	Madin–Darby canine kidney cells
mL	milliliter
<i>n</i>	number of samples tested at the conditions specified
N95	an oil-sensitive respirator that captures ≥95% of challenging 300-nm particles
NIOSH	National Institute for Occupational Safety and Health
nm	nanometer = 10 ⁻⁹ meter
P100	an oil-resistant respirator that captures ≥99.97% of challenging 300-nm particles
pen/strep	a mixture of penicillin and streptomycin used to suppress bacterial colonization
PFE	particle filtration efficiency
PSL	polystyrene latex (beads)
RNA	ribonucleic acid
Sf-EMEM	serum-free Eagle's minimum essential medium
TCID ₅₀	median infective dose in tissue culture
VFE	viable filtration efficiency
μm	micrometer = 10 ⁻⁶ meter
°C	temperature in degrees Celsius